As a general protocol, each transplanted patients gets ciclosporin and tacrolimus as the first line of immunsupressants. The use of CYPtest makes dosing of these drugs personalized and thus patients need less hospitalization and can go home earlier.
CYP3A-status, taking both CYP3A4 expression and CYP3A5 genotype into account, influences recipients’ calcineurin inhibitor therapy after transplantation. In liver transplant patients, CYP3A-status of the donor liver contributes to the recipient’s blood concentrations of ciclosporin and tacrolimus. It has been reported that patients transplanted with liver grafts from low or high expressers or with grafts carrying functional CYP3A5*1 allele required substantial modification of the initial calcineurin inhibitor dose. Donor livers’ CYP3A-status can better identify the risk of calcineurin inhibitor over- or underexposure, and may contribute to the avoidance of misdosing-induced graft injury in the early postoperative period.